StimCell Enegetics

StimCell Enegetics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of StimCell Enegetics (STME) as of Oct 23, 2026 is -820,526.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -504,949.00 USD — a change of 62.50% (lower).

EBITDA

-820,526.00USD

YoY

62.50%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of StimCell Enegetics is 2026 -820,526.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of StimCell Enegetics was 2025 -504,949.00 USD. It decreases by 62.50% lower compared to the previous year.

The StimCell Enegetics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-1.04 M USD
Jan 1, 2020
-1.04 M USD
Jan 1, 2021
-669,293.00 USD
Jan 1, 2022
-670,493.00 USD
Jan 1, 2023
-447,658.00 USD
Jan 1, 2024
-313,430.00 USD
Jan 1, 2025
-504,949.00 USD
Jan 1, 2026
-820,526.00 USD
The StimCell Enegetics EBITDA history
YEAREBITDAYoY
-820,526.00USD+62.50%
-504,949.00USD+61.10%
-313,430.00USD-29.98%
-447,658.00USD-33.23%
-670,493.00USD+0.18%
-669,293.00USD-35.42%
-1.04 MUSD-0.13%
-1.04 MUSD-32.42%
-1.54 MUSD+7.14%
-1.43 MUSD+19.28%
-1.20 MUSD-42.90%
-2.10 MUSD+11,257.76%
-18,527.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of StimCell Enegetics is -820,526.00 USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of StimCell Enegetics changed from -504,949.00 USD to -820,526.00 USD, representing a 62.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s StimCell Enegetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — StimCell Enegetics

All Key Metrics — StimCell Enegetics